A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2001
10/25/2001	WO2001078796A1 Type ii gonadotropin-releasing hormone receptor and polynucleotides encoding therefor
10/25/2001	WO2001078789A2 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001	WO2001078781A2 Methods for prevention and treatment of gastrointestinal disorders
10/25/2001	WO2001078774A2 Recombinant intracellular pathogen vaccines and methods for use
10/25/2001	WO2001078771A1 Method of preventing or treating diabetes
10/25/2001	WO2001078770A1 Inhibition of transmission of tick-borne infections
10/25/2001	WO2001078767A2 Pharmaceutical preparations comprising modified peptides
10/25/2001	WO2001078765A2 Prophylaxis and treatment of diabetes mellitus 1 using proteolytic enzymes
10/25/2001	WO2001078764A1 Treatment of hypertrophic cardiomyopathy with a substance that increases the level of growth hormone receptor antagonists
10/25/2001	WO2001078763A1 Use of npy y1 receptor antagonists in the treatment of inflammatory conditions
10/25/2001	WO2001078762A1 Use of npy y1 receptor agonists in the treatment of pain conditions
10/25/2001	WO2001078761A2 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors
10/25/2001	WO2001078760A2 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001	WO2001078759A1 The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of glomerulosclerosis and renal failure
10/25/2001	WO2001078758A1 Use of substances with oxytocin activity against climacteric disorders
10/25/2001	WO2001078756A2 Agent for postoperative use after the removal of bone tumours
10/25/2001	WO2001078708A1 Treating graft rejection with cxcr3 inhibitors
10/25/2001	WO2001078707A1 Treating graft rejection with ccr5 inhibitors
10/25/2001	WO2001078706A2 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
10/25/2001	WO2001078701A2 Method and compositions for preventing hormone induced adverse effects
10/25/2001	WO2001078700A2 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine
10/25/2001	WO2001078696A2 Formulations for use in inhaler devices
10/25/2001	WO2001078695A2 Pharmaceutical formulations for dry powder inhalers
10/25/2001	WO2001078694A2 Formulations for use in inhaler devices
10/25/2001	WO2001078693A2 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
10/25/2001	WO2001078692A2 Membrane delivery system
10/25/2001	WO2001078688A1 Hydrophilic/lipophilic polymeric matrix dosage formulation
10/25/2001	WO2001078685A1 A method of inducing or enhancing chondrogenesis with extracellular matrix containing bmp-4
10/25/2001	WO2001078683A2 Sustained release formulations comprising growth hormone
10/25/2001	WO2001078682A2 Sustained release drug compositions
10/25/2001	WO2001078653A2 Graft rejection inhibition with ccr2 inhibitors
10/25/2001	WO2001078578A2 Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac
10/25/2001	WO2001078503A2 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
10/25/2001	WO2001056596A8 Use of lysosomal acid lipase for treating atherosclerosis and related diseases
10/25/2001	WO2001039786A3 New uses of suppressive macrophage activation factors
10/25/2001	WO2001036636A3 Human notch ligand proteins and polynucleotides encoding the same
10/25/2001	WO2001034781A3 Lytic enzymes useful for treating fungal infections
10/25/2001	WO2001027159A3 Polypeptides for detection and elimination of ca19-9 antigen positive cells
10/25/2001	WO2001026679A3 T-cells and molecules involved in immune regulation
10/25/2001	WO2001024765A3 Antigenic modification of polypeptides
10/25/2001	WO2001023570A3 Methods and compositions relating to sodium channel beta-1a subunits
10/25/2001	WO2001023421A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
10/25/2001	WO2001022091A3 Method for determining the fertility of mammals, especially of humans
10/25/2001	WO2001021794A3 Smad associating polypeptides
10/25/2001	WO2001021643A3 Parathyroid hormone analogues for the treatment of osteoporosis
10/25/2001	WO2001021154A3 Surface modified particulate compositions of biologically active substances
10/25/2001	WO2001018044A3 Use of semaphorin for modulation of cellular efflux
10/25/2001	WO2001012790A3 Isomerase proteins
10/25/2001	WO2001012663A3 Hematopoietic regulatory factors and methods of use thereof
10/25/2001	WO2001012126A3 Cardiomyocyte regeneration
10/25/2001	WO2000068249A3 Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses therefor
10/25/2001	WO2000061541A8 Pharmaceutical compounds
10/25/2001	WO2000047618A9 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
10/25/2001	WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions
10/25/2001	WO2000040605A9 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
10/25/2001	WO2000011169A3 Human cell signaling proteins (csig)
10/25/2001	US20010034436 Polynucleotide and polypeptides, screening for antibiotic activity, Staphylococcus
10/25/2001	US20010034433 Inhibition of growth of somatomedin dependent cancers, the effect of somatomedin-c in acromegaly, the growth of retinal blood vessels and fibrous tissues in diabetic retinopathy, growth of tall children, etc.; antiscarring agents
10/25/2001	US20010034362 Pyrrolidine derivatives for vision and memory disorders
10/25/2001	US20010034334 Genetic engineered polypeptide
10/25/2001	US20010034331 Isolated polypeptide
10/25/2001	US20010034329 Nucleic acids
10/25/2001	US20010034327 Suppression of inhibitors
10/25/2001	US20010034326 Therapy for hematopoietic neoplasma
10/25/2001	US20010034325 Dietary modulators of gamma glutamyl transpeptidase
10/25/2001	US20010034324 Immunostimulation
10/25/2001	US20010034323 Superoxygenating blood substitutes based on hemoglobin, nitric oxide and cyclic GMP generating compositions
10/25/2001	US20010034322 Taxol-like protein (TALP) and process for preparing the same
10/25/2001	US20010034321 Salts with polycations such as chitosan; treatment of skin disorders
10/25/2001	US20010034061 Culturing a population of mammalian cells capable of forming a solid tissue in a medium with oxygen level selected to enhance survival of the stem or progenitor cell type; subatmospheric oxygen; drug screening
10/25/2001	US20010034052 A breast tumor polypeptide(s), immunogenic portions thereof, polynucleotides that encode such peptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides; vaccines
10/25/2001	US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
10/25/2001	US20010034042 Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
10/25/2001	US20010034035 Amino acid sequences derived partially from ependymin that binds with calcium; stroke and other neurodegenerative diseases; antiischemic agents; cognition activators; conjugated to transfer through blood-brain barrier
10/25/2001	US20010034032 Determining a subject's susceptibility to or the rapidity of progression of sepsis in a subject by detecting at least one allele of an Interleukin-1 proinflammatory haplotype in a nucleic acid sample which indicates increased susceptibility
10/25/2001	US20010034021 Antibodies that specifically react with seroreactive regions on HPV 16 proteins E1 and E2
10/25/2001	US20010033868 Biodegradable polymer
10/25/2001	US20010033856 High protein
10/25/2001	US20010033844 Human Herpesvirus 6A and 6B transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis
10/25/2001	US20010033842 Immunoglobulin antagonist
10/25/2001	US20010033841 Atherosclerosis therapy
10/25/2001	US20010033840 Methods for inducing T cell tolerance to a tissue or organ graft
10/25/2001	US20010033837 Mixture containing stabilizer
10/25/2001	US20010033836 Transgenic autologous T-cell therapy in humans, and related compositions and kits
10/25/2001	US20010033827 Inhibition of mucin release from airway goblet cells by polycationic peptides
10/25/2001	DE10020125A1 Agent for stimulating bone regrowth, useful as insert after surgery for bone cancer, comprises single sequence expressing a fusion of growth factor and protease inhibitor
10/25/2001	DE10016846A1 New cell constructs from activated T-cells of patients useful as a medicament
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2485920A1 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001	CA2485919A1 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001	CA2409190A1 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001	CA2406955A1 Sheep lice, bovicola ovis, allergen treatment
10/25/2001	CA2406953A1 A glycopeptide and preparation thereof
10/25/2001	CA2406947A1 Methods for prevention and treatment of gastrointestinal disorders
10/25/2001	CA2406590A1 Agent for postoperative use after the removal of bone tumours
10/25/2001	CA2406475A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/25/2001	CA2406403A1 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001	CA2406390A1 Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
10/25/2001	CA2406245A1 Il-174 uses, compositions and methods
10/25/2001	CA2406213A1 Compositions and methods for the therapy and diagnosis of breast cancer

1 ... 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 ... 3163